Lexicon Pharmaceuticals (LXRX) Assets (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Assets data on file, last reported at $268.8 million in Q1 2026.

• Quarterly Assets fell 9.69% year-over-year to $268.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268.8 million (down 9.69% YoY) and the FY2025 annual result came in at $185.0 million, down 38.01% from the prior year.
• Assets rose to $268.8 million in Q1 2026 per LXRX's latest filing, from $185.0 million in the prior quarter.
• Across five years, Assets topped out at $417.2 million in Q1 2024 and bottomed at $112.3 million in Q2 2022.
• The 5-year median for Assets is $229.4 million (2023), against an average of $247.8 million.
• The widest annual swing landed in 2023, when Assets jumped 181.97%; it then tumbled 39.58% in 2025.
• Tracing LXRX's Assets over 5 years: stood at $194.3 million in 2022, then grew by 18.08% to $229.4 million in 2023, then jumped by 30.07% to $298.4 million in 2024, then tumbled by 38.01% to $185.0 million in 2025, then soared by 45.32% to $268.8 million in 2026.
• Per Business Quant, the three latest LXRX Assets figures stand at $268.8 million (Q1 2026), $185.0 million (Q4 2025), and $205.9 million (Q3 2025).

Peer Comparison